A phase I/II trial of DEP® Cabazitaxel

Trial Profile

A phase I/II trial of DEP® Cabazitaxel

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Jan 2018

At a glance

  • Drugs Cabazitaxel (Primary)
  • Indications Breast cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 31 Jan 2018 Status changed from planning to not yet recruiting according to a Starpharma media release.
    • 31 Jan 2018 According to a Starpharma media release, the company has received regulatory and ethics approval to commence this trial.
    • 30 Jan 2018 Patient gender and indiacation are assumed from RDI.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top